Previous 10 | Next 10 |
Advanced OpRegen ® For Dry AMD in Phase 2a Study in Collaboration with Roche and Genentech Closed $14 Million Registered Direct Offering OPC1 Investigational New Drug Amendment Cleared; New Clinical Trial Planned Initiated Development of Hypoimmune iPSC Cell Line ...
2024-03-06 17:35:34 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Financial informat...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 20...
The DOSED Clinical Study Will Evaluate a Novel Delivery Device in Subacute and Chronic Spinal Cord Injury Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ann...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the ...
2024-02-06 09:21:14 ET More on Lineage Cell Therapeutics Lineage Cell Therapeutics: Not Yet Attractive Stem Cell Company Seeking Alpha’s Quant Rating on Lineage Cell Therapeutics Historical earnings data for Lineage Cell Therapeutics Read the full ar...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into a definitive agreement with certain investors for the purchase and sale of 13,461,540 of the ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results showing retinal structure improvements with RG6501( OpRegen ) from a Phase 1/2a clinical study (C...
2024-01-15 03:12:29 ET Summary Lineage Cell Therapeutics develops cell therapies for degenerative diseases, with 5 cell types in active development. The company has treated over 50 patients with no rejections and has seen 5 cases of retinal regeneration on a single administration ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that the Company has submitted an Investigational New Drug amendment (INDa) to the U.S. Food and Drug Administrati...
News, Short Squeeze, Breakout and More Instantly...
BioTime Inc. Company Name:
LCTX Stock Symbol:
NYSE Market:
Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit OpRegen Preclinical Results Pre...
BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10) BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5) Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) laye...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the...